Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 427 entries
Sorted by: Best Match Show Resources per page
A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury.

Neuro-oncology advances

Tang TT, Zawaski JA, Kesler SR, Beamish CA, Reddick WE, Glass JO, Carney DH, Sabek OM, Grosshans DR, Gaber MW.
PMID: 31608330
Neurooncol Adv. 2019 May-Dec;1(1):vdz012. doi: 10.1093/noajnl/vdz012. Epub 2019 Jul 02.

BACKGROUND: Cranial radiotherapy (CRT) is an important part of brain tumor treatment, and although highly effective, survivors suffer from long-term cognitive side effects. In this study we aim to establish late-term imaging markers of CRT-induced brain injury and identify...

Cite
Tang TT, Zawaski JA, Kesler SR, et al. A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury. Neurooncol Adv. 2019;1(1):vdz012doi: 10.1093/noajnl/vdz012.
Tang, T. T., Zawaski, J. A., Kesler, S. R., Beamish, C. A., Reddick, W. E., Glass, J. O., Carney, D. H., Sabek, O. M., Grosshans, D. R., & Gaber, M. W. (2019). A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury. Neuro-oncology advances, 1(1), vdz012. https://doi.org/10.1093/noajnl/vdz012
Tang, Tien T, et al. "A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury." Neuro-oncology advances vol. 1,1 (2019): vdz012. doi: https://doi.org/10.1093/noajnl/vdz012
Tang TT, Zawaski JA, Kesler SR, Beamish CA, Reddick WE, Glass JO, Carney DH, Sabek OM, Grosshans DR, Gaber MW. A comprehensive preclinical assessment of late-term imaging markers of radiation-induced brain injury. Neurooncol Adv. 2019 May-Dec;1(1):vdz012. doi: 10.1093/noajnl/vdz012. Epub 2019 Jul 02. PMID: 31608330; PMCID: PMC6777502.
Copy Download .nbib Format: NLM
Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma.

Neuro-oncology advances

Kam KL, Snuderl M, Khan O, Wolinsky JP, Gondi V, Grimm S, Horbinski C.
PMID: 32002518
Neurooncol Adv. 2020 Jan-Dec;2(1):vdz057. doi: 10.1093/noajnl/vdz057. Epub 2019 Dec 27.

No abstract available.

Cite
Kam KL, Snuderl M, Khan O, et al. Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma. Neurooncol Adv. 2019;2(1):vdz057doi: 10.1093/noajnl/vdz057.
Kam, K. L., Snuderl, M., Khan, O., Wolinsky, J. P., Gondi, V., Grimm, S., & Horbinski, C. (2020). Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma. Neuro-oncology advances, 2(1), vdz057. https://doi.org/10.1093/noajnl/vdz057
Kam, Kwok-Ling, et al. "Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma." Neuro-oncology advances vol. 2,1 (2020): vdz057. doi: https://doi.org/10.1093/noajnl/vdz057
Kam KL, Snuderl M, Khan O, Wolinsky JP, Gondi V, Grimm S, Horbinski C. Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma. Neurooncol Adv. 2020 Jan-Dec;2(1):vdz057. doi: 10.1093/noajnl/vdz057. Epub 2019 Dec 27. PMID: 32002518; PMCID: PMC6978194.
Copy Download .nbib Format: NLM
Sox2.

Neuro-oncology advances

Treisman DM, Li Y, Pierce BR, Li C, Chervenak AP, Tomasek GJ, Lozano G, Zheng X, Kool M, Zhu Y.
PMID: 31763624
Neurooncol Adv. 2019 May-Dec;1(1):vdz027. doi: 10.1093/noajnl/vdz027. Epub 2019 Sep 23.

BACKGROUND: High-intensity therapy effectively treats most METHODS: Using mouse SHH-MB models with different p53 activities, we investigated therapeutic efficacy by activating p53-mediated cell-cycle arrest versus p53-mediated apoptosis on radiation-induced recurrence.RESULTS: Upon radiation treatment, p53CONCLUSIONS: Quiescent Sox2

Cite
Treisman DM, Li Y, Pierce BR, et al. Sox2. Neurooncol Adv. 2019;1(1):vdz027doi: 10.1093/noajnl/vdz027.
Treisman, D. M., Li, Y., Pierce, B. R., Li, C., Chervenak, A. P., Tomasek, G. J., Lozano, G., Zheng, X., Kool, M., & Zhu, Y. (2019). Sox2. Neuro-oncology advances, 1(1), vdz027. https://doi.org/10.1093/noajnl/vdz027
Treisman, Daniel M, et al. "Sox2." Neuro-oncology advances vol. 1,1 (2019): vdz027. doi: https://doi.org/10.1093/noajnl/vdz027
Treisman DM, Li Y, Pierce BR, Li C, Chervenak AP, Tomasek GJ, Lozano G, Zheng X, Kool M, Zhu Y. Sox2. Neurooncol Adv. 2019 May-Dec;1(1):vdz027. doi: 10.1093/noajnl/vdz027. Epub 2019 Sep 23. PMID: 31763624; PMCID: PMC6860004.
Copy Download .nbib Format: NLM
The invasive proteome of glioblastoma revealed by laser-capture microdissection.

Neuro-oncology advances

Daubon T, Guyon J, Raymond AA, Dartigues B, Rudewicz J, Ezzoukhry Z, Dupuy JW, Herbert JMJ, Saltel F, Bjerkvig R, Nikolski M, Bikfalvi A.
PMID: 32642662
Neurooncol Adv. 2019 Sep 28;1(1):vdz029. doi: 10.1093/noajnl/vdz029. eCollection 2019.

BACKGROUND: Glioblastomas are heterogeneous tumors composed of a necrotic and tumor core and an invasive periphery.METHODS: Here, we performed a proteomics analysis of laser-capture micro-dissected glioblastoma core and invasive areas of patient-derived xenografts.RESULTS: Bioinformatics analysis identified enriched proteins in...

Cite
Daubon T, Guyon J, Raymond AA, et al. The invasive proteome of glioblastoma revealed by laser-capture microdissection. Neurooncol Adv. 2019;1(1):vdz029doi: 10.1093/noajnl/vdz029.
Daubon, T., Guyon, J., Raymond, A. A., Dartigues, B., Rudewicz, J., Ezzoukhry, Z., Dupuy, J. W., Herbert, J. M. J., Saltel, F., Bjerkvig, R., Nikolski, M., & Bikfalvi, A. (2019). The invasive proteome of glioblastoma revealed by laser-capture microdissection. Neuro-oncology advances, 1(1), vdz029. https://doi.org/10.1093/noajnl/vdz029
Daubon, Thomas, et al. "The invasive proteome of glioblastoma revealed by laser-capture microdissection." Neuro-oncology advances vol. 1,1 (2019): vdz029. doi: https://doi.org/10.1093/noajnl/vdz029
Daubon T, Guyon J, Raymond AA, Dartigues B, Rudewicz J, Ezzoukhry Z, Dupuy JW, Herbert JMJ, Saltel F, Bjerkvig R, Nikolski M, Bikfalvi A. The invasive proteome of glioblastoma revealed by laser-capture microdissection. Neurooncol Adv. 2019 Sep 28;1(1):vdz029. doi: 10.1093/noajnl/vdz029. eCollection 2019. PMID: 32642662; PMCID: PMC7212852.
Copy Download .nbib Format: NLM
The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis.

Neuro-oncology advances

Wei CJ, Gu SC, Ren JY, Gu YH, Xu XW, Chou X, Lian X, Huang X, Li HZ, Gao YS, Gu B, Zan T, Wang ZC, Li QF.
PMID: 32642666
Neurooncol Adv. 2019 Oct 18;1(1):vdz037. doi: 10.1093/noajnl/vdz037. eCollection 2019.

The immune system plays an essential role in the development of tumors, which has been demonstrated in multiple types of cancers. Consistent with this, immunotherapies with targets that disrupt these mechanisms and turn the immune system against developing cancers...

Cite
Wei CJ, Gu SC, Ren JY, et al. The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis. Neurooncol Adv. 2019;1(1):vdz037doi: 10.1093/noajnl/vdz037.
Wei, C. J., Gu, S. C., Ren, J. Y., Gu, Y. H., Xu, X. W., Chou, X., Lian, X., Huang, X., Li, H. Z., Gao, Y. S., Gu, B., Zan, T., Wang, Z. C., & Li, Q. F. (2019). The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis. Neuro-oncology advances, 1(1), vdz037. https://doi.org/10.1093/noajnl/vdz037
Wei, Cheng-Jiang, et al. "The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis." Neuro-oncology advances vol. 1,1 (2019): vdz037. doi: https://doi.org/10.1093/noajnl/vdz037
Wei CJ, Gu SC, Ren JY, Gu YH, Xu XW, Chou X, Lian X, Huang X, Li HZ, Gao YS, Gu B, Zan T, Wang ZC, Li QF. The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis. Neurooncol Adv. 2019 Oct 18;1(1):vdz037. doi: 10.1093/noajnl/vdz037. eCollection 2019. PMID: 32642666; PMCID: PMC7212924.
Copy Download .nbib Format: NLM
Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis.

Neuro-oncology advances

De Leeuw BI, Van Baarsen KM, Snijders TJ, Robe PAJT.
PMID: 32642663
Neurooncol Adv. 2019 Oct 01;1(1):vdz032. doi: 10.1093/noajnl/vdz032. eCollection 2019.

BACKGROUND: The introduction of the 2016 WHO Classification of Tumors of the Central Nervous System has resulted in tumor groupings with improved prognostic value for diffuse glioma patients. Molecular subtype, primarily based on IDH-mutational status and 1p/19q-status, is a...

Cite
De Leeuw BI, Van Baarsen KM, Snijders TJ, et al. Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. Neurooncol Adv. 2019;1(1):vdz032doi: 10.1093/noajnl/vdz032.
De Leeuw, B. I., Van Baarsen, K. M., Snijders, T. J., & Robe, P. A. J. T. (2019). Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. Neuro-oncology advances, 1(1), vdz032. https://doi.org/10.1093/noajnl/vdz032
De Leeuw, Beverly I, et al. "Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis." Neuro-oncology advances vol. 1,1 (2019): vdz032. doi: https://doi.org/10.1093/noajnl/vdz032
De Leeuw BI, Van Baarsen KM, Snijders TJ, Robe PAJT. Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. Neurooncol Adv. 2019 Oct 01;1(1):vdz032. doi: 10.1093/noajnl/vdz032. eCollection 2019. PMID: 32642663; PMCID: PMC7212862.
Copy Download .nbib Format: NLM
Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI.

Neuro-oncology advances

Galldiks N, Werner JM, Tscherpel C, Fink GR, Langen KJ.
PMID: 32642667
Neurooncol Adv. 2019 Oct 20;1(1):vdz038. doi: 10.1093/noajnl/vdz038. eCollection 2019.

No abstract available.

Cite
Galldiks N, Werner JM, Tscherpel C, et al. Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. Neurooncol Adv. 2019;1(1):vdz038doi: 10.1093/noajnl/vdz038.
Galldiks, N., Werner, J. M., Tscherpel, C., Fink, G. R., & Langen, K. J. (2019). Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. Neuro-oncology advances, 1(1), vdz038. https://doi.org/10.1093/noajnl/vdz038
Galldiks, Norbert, et al. "Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI." Neuro-oncology advances vol. 1,1 (2019): vdz038. doi: https://doi.org/10.1093/noajnl/vdz038
Galldiks N, Werner JM, Tscherpel C, Fink GR, Langen KJ. Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. Neurooncol Adv. 2019 Oct 20;1(1):vdz038. doi: 10.1093/noajnl/vdz038. eCollection 2019. PMID: 32642667; PMCID: PMC7212846.
Copy Download .nbib Format: NLM
Gliomas display distinct sex-based differential methylation patterns based on molecular subtype.

Neuro-oncology advances

Johansen ML, Stetson LC, Vadmal V, Waite K, Berens ME, Connor JR, Lathia J, Rubin JB, Barnholtz-Sloan JS.
PMID: 32642674
Neurooncol Adv. 2020 Jan 08;2(1):vdaa002. doi: 10.1093/noajnl/vdaa002. eCollection 2020.

BACKGROUND: Gliomas are the most common type of primary brain tumor and one of many cancers where males are diagnosed with greater frequency than females. However, little is known about the sex-based molecular differences in glioblastomas (GBMs) or lower...

Cite
Johansen ML, Stetson LC, Vadmal V, et al. Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. Neurooncol Adv. 2020;2(1):vdaa002doi: 10.1093/noajnl/vdaa002.
Johansen, M. L., Stetson, L. C., Vadmal, V., Waite, K., Berens, M. E., Connor, J. R., Lathia, J., Rubin, J. B., & Barnholtz-Sloan, J. S. (2020). Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. Neuro-oncology advances, 2(1), vdaa002. https://doi.org/10.1093/noajnl/vdaa002
Johansen, Mette L, et al. "Gliomas display distinct sex-based differential methylation patterns based on molecular subtype." Neuro-oncology advances vol. 2,1 (2020): vdaa002. doi: https://doi.org/10.1093/noajnl/vdaa002
Johansen ML, Stetson LC, Vadmal V, Waite K, Berens ME, Connor JR, Lathia J, Rubin JB, Barnholtz-Sloan JS. Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. Neurooncol Adv. 2020 Jan 08;2(1):vdaa002. doi: 10.1093/noajnl/vdaa002. eCollection 2020. PMID: 32642674; PMCID: PMC7212920.
Copy Download .nbib Format: NLM
Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells.

Neuro-oncology advances

Ferluga S, Baiz D, Hilton DA, Adams CL, Ercolano E, Dunn J, Bassiri K, Kurian KM, Hanemann CO.
PMID: 32642677
Neurooncol Adv. 2020 Jan 21;2(1):vdaa008. doi: 10.1093/noajnl/vdaa008. eCollection 2020.

BACKGROUND: Meningiomas are the most frequent primary brain tumors of the central nervous system. The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not available yet. The well-characterized genetic background stratifies these tumors in several...

Cite
Ferluga S, Baiz D, Hilton DA, et al. Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells. Neurooncol Adv. 2020;2(1):vdaa008doi: 10.1093/noajnl/vdaa008.
Ferluga, S., Baiz, D., Hilton, D. A., Adams, C. L., Ercolano, E., Dunn, J., Bassiri, K., Kurian, K. M., & Hanemann, C. O. (2020). Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells. Neuro-oncology advances, 2(1), vdaa008. https://doi.org/10.1093/noajnl/vdaa008
Ferluga, Sara, et al. "Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells." Neuro-oncology advances vol. 2,1 (2020): vdaa008. doi: https://doi.org/10.1093/noajnl/vdaa008
Ferluga S, Baiz D, Hilton DA, Adams CL, Ercolano E, Dunn J, Bassiri K, Kurian KM, Hanemann CO. Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells. Neurooncol Adv. 2020 Jan 21;2(1):vdaa008. doi: 10.1093/noajnl/vdaa008. eCollection 2020. PMID: 32642677; PMCID: PMC7212880.
Copy Download .nbib Format: NLM
Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization.

Neuro-oncology advances

Huizer K, Sacchetti A, Swagemakers S, van der Spek PJ, Dik W, Mustafa DA, Kros JM.
PMID: 32642695
Neurooncol Adv. 2020 Apr 01;2(1):vdaa040. doi: 10.1093/noajnl/vdaa040. eCollection 2020.

BACKGROUND: In order to identify suitable therapeutic targets for glioma anti-angiogenic therapy, the process of neovascularization mediated by circulating angiogenic cells (CACs) needs to be scrutinized.METHODS: In the present study, we compared the expression of neovascularization-related genes by 3...

Cite
Huizer K, Sacchetti A, Swagemakers S, et al. Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization. Neurooncol Adv. 2020;2(1):vdaa040doi: 10.1093/noajnl/vdaa040.
Huizer, K., Sacchetti, A., Swagemakers, S., van der Spek, P. J., Dik, W., Mustafa, D. A., & Kros, J. M. (2020). Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization. Neuro-oncology advances, 2(1), vdaa040. https://doi.org/10.1093/noajnl/vdaa040
Huizer, Karin, et al. "Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization." Neuro-oncology advances vol. 2,1 (2020): vdaa040. doi: https://doi.org/10.1093/noajnl/vdaa040
Huizer K, Sacchetti A, Swagemakers S, van der Spek PJ, Dik W, Mustafa DA, Kros JM. Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization. Neurooncol Adv. 2020 Apr 01;2(1):vdaa040. doi: 10.1093/noajnl/vdaa040. eCollection 2020. PMID: 32642695; PMCID: PMC7276933.
Copy Download .nbib Format: NLM
Missing diversity in brain tumor trials.

Neuro-oncology advances

Taha B, Winston G, Tosi U, Hartley B, Hoffman C, Dahmane N, Mason CE, Greenfield JP.
PMID: 32642711
Neurooncol Adv. 2020 May 13;2(1):vdaa059. doi: 10.1093/noajnl/vdaa059. eCollection 2020.

BACKGROUND: Clinical trials for brain tumors represent a significant opportunity for both patients and providers to understand and combat a disease with substantial morbidity. The aim of this study was to quantify and map ethnic and racial representation in...

Cite
Taha B, Winston G, Tosi U, et al. Missing diversity in brain tumor trials. Neurooncol Adv. 2020;2(1):vdaa059doi: 10.1093/noajnl/vdaa059.
Taha, B., Winston, G., Tosi, U., Hartley, B., Hoffman, C., Dahmane, N., Mason, C. E., & Greenfield, J. P. (2020). Missing diversity in brain tumor trials. Neuro-oncology advances, 2(1), vdaa059. https://doi.org/10.1093/noajnl/vdaa059
Taha, Birra, et al. "Missing diversity in brain tumor trials." Neuro-oncology advances vol. 2,1 (2020): vdaa059. doi: https://doi.org/10.1093/noajnl/vdaa059
Taha B, Winston G, Tosi U, Hartley B, Hoffman C, Dahmane N, Mason CE, Greenfield JP. Missing diversity in brain tumor trials. Neurooncol Adv. 2020 May 13;2(1):vdaa059. doi: 10.1093/noajnl/vdaa059. eCollection 2020. PMID: 32642711; PMCID: PMC7316223.
Copy Download .nbib Format: NLM
Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation.

Neuro-oncology advances

Turnquist C, Harris BT, Harris CC.
PMID: 32642709
Neurooncol Adv. 2020 May 05;2(1):vdaa057. doi: 10.1093/noajnl/vdaa057. eCollection 2020.

Continued improvements in cancer therapies have increased the number of long-term cancer survivors. Radiation therapy remains one of the primary treatment modalities with about 60% of newly diagnosed cancer patients receiving radiation during the course of their disease. While...

Cite
Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neurooncol Adv. 2020;2(1):vdaa057doi: 10.1093/noajnl/vdaa057.
Turnquist, C., Harris, B. T., & Harris, C. C. (2020). Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neuro-oncology advances, 2(1), vdaa057. https://doi.org/10.1093/noajnl/vdaa057
Turnquist, Casmir, et al. "Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation." Neuro-oncology advances vol. 2,1 (2020): vdaa057. doi: https://doi.org/10.1093/noajnl/vdaa057
Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neurooncol Adv. 2020 May 05;2(1):vdaa057. doi: 10.1093/noajnl/vdaa057. eCollection 2020. PMID: 32642709; PMCID: PMC7271559.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 427 entries